Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. Historically, treatment of pediatric CD would begin with safe, albeit often less-efficacious, conventional agents (e.g., 5-ASAs) and then progress to more-potent drugs, such as biologics and/or immunosuppressants. However, this scenario has changed, and more physicians are now prescribing biologics, especially TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira), as first-line therapy for recently diagnosed pediatric CD patients. The non-TNF biologics, including Takeda’s Entyvio and Janssen’s Stelara, may also be prescribed, particularly after anti-TNF failure.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Janssen, Takeda, AbbVie, UCB
Key drugs: Humira, Remicade, biosimilar infliximab, Entyvio, Stelara, Cimzia, aminosalicylates, immunosuppressants